Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LBL-007 in Combination With Toripalimab in the Treatment of Advanced Malignancies

Next Previous
X
Search
Trial Profile

A Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LBL-007 in Combination With Toripalimab in the Treatment of Advanced Malignancies

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LBL-007 (Primary) ; Toripalimab (Primary)
  • Indications Head and neck cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Leads Biolabs

    • Most Recent Events

    • 16 Aug 2024 Planned End Date changed from 14 Dec 2024 to 14 Mar 2025.
    • 16 Aug 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Dec 2024.
    • 10 Apr 2024 Preliminary results (by December 1, 2023, n=80 ) assessing safety and efficacy of LBL-007 in combination with toripalimab, in patients with advanced malignant tumors presented at the 115th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top